



ASX : IPD

30th April 2009

ASX ANNOUNCEMENT – QUARTERLY UPDATE

In conjunction with the release of its quarterly cashflow report, ImpediMed Limited is pleased to provide the following update:

The group is continuing to direct its primary business creation focus towards its new L-Dex operating lease for Breast Surgeons and Oncologists in the US market, and is making good progress with greater than 25 new agreements signed in the quarter. The company is gathering good data on clinician's experiences in achieving reimbursement under existing miscellaneous reimbursement codes, and expects this data to assist in driving agreements out of their qualification period and into direct billing in the months ahead.

Highlights for the quarter ending 31st March 2009 include the following:

- Sales revenues for the quarter were \$AU 824k versus \$AU 718k for the quarter ended 31st December 2008, up 15%.
- Receipts from customers for the quarter were \$AU 1,032k versus \$AU 687k for the quarter ended 31st December 2008, up 50%
- Net operating cashflows for the quarter were negative (\$AU 2,660k) versus negative (\$AU 3,308k) for the quarter ended 31st December 2008, a decrease in operating cash burn of 20%.
- External R&D project costs for the quarter dropped to \$AU 459k, versus the previous quarter expense of \$AU 1,534k. As flagged at the half year the company's project to develop its next generation device reached prototype stage around the end of January, bringing to an end the costly external development phase of the project. The device will be in a clinical evaluation, and market feedback cycle for the next couple of quarters, meaning external R&D costs will be substantially reduced through those phases.
- Cash at the end of the quarter was \$AU 3,968k.

The company is restricting spending and managing its cash closely, and would expect to further reduce cash utilization in the coming quarters.

Interest in, and support for the company was reinforced during the quarter with a placement on 30th January of \$AU 2 Million at 70 cents per ordinary share to an Institutional investor.

For more information:

Greg Brown

CEO & Director

+61 (7) 3860-3700